AzTrials
AzTrials

Tracheal Intubation MorbidityMPLITNCT01118533

Impact of Blades Used for Scheduled Orotracheal Intubation on Postoperative Sore Throat

A study testing metal reusable blades MacIntosh and Single use plastic blades HEINE XP® in people with Tracheal Intubation Morbidity and Sore Throat, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Orotracheal intubation following general anesthesia requires blades to be performed. The risk of patients contamination with infectious agents related to reusable metal blades leads to promote single-use blades. Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Tracheal Intubation Morbidity, Sore Throat
What is being tested?
metal reusable blades MacIntosh and Single use plastic blades HEINE XP®
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
712 participants
Where
1 siteFrance
Study dates
Sep 2010to Sep 2015
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patient, 18-70 years-old scheduled for surgery planned under general anesthesia with orotracheal intubation
  • Patient who has underwent a clinical examination before inclusion
  • Patient who has carefully read the information notice and is not opposed to participate to the study
  • Patient having a assurance policy or a similar regimen

Who cannot join

  • Pregnancy
  • Difficulty to understand the current language (French)
  • Presence of predictive factors of difficult orotracheal intubation
  • Previous difficult tracheal intubation Grade IV of the MALLANPETI score Limited mouth opening (inter-incisive distance < 3.5 cm) Limited cervical mobility Thyromental distance < 6 cm History of radiotherapy or surgery for ENT cancer Retrognathism Presence of gastric tube for postoperative purposes Presence of Pharyngeal and Laryngeal signs before surgery
  • Type of surgery Surgery performed without orotracheal intubation Thyroid surgery ENT surgery Withdrawal of gastric banding Bariatric surgery Ambulatory surgery (one-day surgery)

Trial locations and contacts

1 site in 1 country.

France1 site
  • hospital Center of Meaux, department of anesthesiology

    Meaux, Meaux, 77104

Other trials in France

About this study

Official title: A Prospective, Multicenter, Randomized and Single Bind Trial. Influence of Laryngoscope Blade Material on Postoperative PHARYNGEAL AND LARYNGEAL Morbidity Following Scheduled OroTracheal Intubation

Orotracheal intubation following general anesthesia requires blades to be performed. The risk of patients contamination with infectious agents related to reusable metal blades leads to promote single-use blades. Some of these latter are plastic and this material may need more strength to lift the jaw and expose the larynx before orotracheal intubation. Sometimes, change of blade, from plastic to metal, during the procedure is necessary to increase the larynx exposure. This change of blade may increase the frequency of sore throat following orotracheal intubation.

Consequently, the study hypothesis is an increase of both sore throat intensity and frequency with the plastic blades compared with the metal blades.

The primary purpose of the present study is to compare the impact of these two types of blades, metal versus plastic, on sore throat intensity and frequency following scheduled orotracheal intubation for general anesthesia

Read the detailed description

Trial design :

This will be a multicenter, prospective, randomized and single-blind controlled study

Material and Methods :

The obtaining of the Ethic Committee approval allows the enrolment of 712 patients scheduled for surgery performed under general anesthesia with orotracheal intubation. Adult patients, 18 to 70 years-old, with grade I-II of ASA (American Society of Anesthesiology) status will be enrolled after clear information and obtaining, at the anesthesia visit, of the non-opposition to be enrolled in the trial.

At the anesthesia visit, the anesthesiologist will explain the purpose and protocol to the patients and then will propose them to participate to the study. The decision to be enrolled will be known at the pre-anesthesia visit, one day before the surgery. Therefore, the patients will have a delay between the anesthesia and pre-anesthesia visits to make a decision. The non-opposition to participate to the trial will be clearly mentioned in the medical file.

A randomization list will be established by a statistician. Informed and non-opposed patients will be allocated both a randomization number and a plastic or metal blade in the operating theatre via the Clean Web software.

The evaluation and measure of the primary outcome will be made in a single-blind way. The patients will evaluate the sore throat intensity being unaware of the type of blade used for the orotracheal intubation. An independent research assistant in each centre will collect data evaluated in both the operating room during the orotracheal intubation procedure and the post-operative period.

The duration of tracheal intubation will be defined as the time elapsing from the mouth insertion of the blade to the passage of the tube throughout the vocal cords announced by the operator. The intra-tracheal position of the tube will be confirmed by three squared cycles of capnography.

Protocol :

Anesthesia and monitoring:

Patients will be premedicated by hydroxyzine 1 mg kg-1 the previous evening and one hour before the transfer to the operating room.

The randomization is performed in the operating room just before the anesthesia induction.

The monitoring will be standard with:

  • An electrocardiogram (lookout of cardiac rhythm modifications)
  • A pulse oxymetry to lookout arterial oxygen saturation
  • A non-invasive blood pressure monitoring
  • A capnograph to lookout carbon dioxide elimination in the expired gas and to confirm the intra-tracheal position of the tube
  • A gas analyser to control the concentration of administered halogenated volatile agents
  • A neuromuscular blockade monitor to lookout the depth of the neuromuscular blockade required to perform tracheal intubation in optimal conditions. The monitoring will consist of stimulating the facial nerve 1 cm near the external eyelid corner by a train of four electric charges (30 mA). The muscular responses will be evaluated on the corrugator Supercilia by counting the number of contractions.
  • A bispectral index (BIS) or entropy to monitor the hypnosis depth. The expected values will be 40-60 and 25-35, respectively.
  • A manometer to control the tracheal tube cuff pressure Before anesthesia induction, patients will breathe 100% oxygen till expired oxygen concentration reach 90%. Intravenous anesthesia will be then performed with propofol (1.5-2.5 mg kg -1) as hypnotic, sufentanil (0.2 mcg kg-1) and atracurium (0.5 mg kg-1) as muscle relaxant. Cis-atracurium or vecuronium as middle acting muscle relaxant or SUNCCYNILCHOLINE as short acting muscle relaxant will be authorized. According to the randomization, the blade used for orotracheal intubation will be metal or plastic. The metal blade is reusable and the plastic blade is disposable. When the BIS or the entropy will reach 40-60 and 25-35, respectively, with efficient face mask ventilation (good thoracic amplitude following by capnography cycles), no response to the TOF at the corrugator Supercilia, the laryngoscopy will be performed according to the orotracheal intubation algorithm. Tracheal tube sizes will be 7 mm for female and 7.5 for males. Tracheal tube cuff will be standard.

After tracheal intubation, the anesthesia will be maintained with inhaled halogenated gas or intravenously. Inhaled gas will be moistened. Postoperative analgesia will be anticipated in the operating room with paracetamol 1 g, ketoprofen 100 mg and nefopam if necessary. In the absence of contraindication, the three analgesics will be administered during laparotomies. Wound and abdominal holes for laparoscopy will be infiltrated with ropivacaine. At the end of the surgery, the tracheal tube will be withdrawn according to the standard procedure recommended by the French Anesthesiology Society. Mouth secretions will be suctioned delicately. In the PACU, analgesia will be continued with according to a protocol adapted to the type of surgery. Morphine will be administered if pain VAS reaches 4/10. Pharyngeal and laryngeal morbidity evaluation will begin at the discharge of the PACU and will last 48 hours. If signs persist more than 48 hours, an ENT examination will be performed to make a diagnostic.

Statistics :

Sample size: The literature reports a 30% incidence of postoperative sore throat with metal blades. The hypothesis is that this incidence could increase from 30% to 40% if plastic blades are used. Un sample size of 356 patients per group is required to detect this increase of 10% with a Chi2 test, a statistic power (1-beta) of 0.80 and alpha type I error probability of 0.05.

Being tested
metal reusable blades MacIntosh, Single use plastic blades HEINE XP®
Keywords
Intubation, Sore throat, Blades, Laryngoscopy, Morbidity
Medical subject headings
Pharyngitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • metal reusable blades MacIntoshDevice

    laryngoscope blades

  • Single use plastic blades HEINE XP®Device

    Also called Sign use plastic blades HEINE XP®

    laryngoscope blades

Study groups in NCT01118533
Study groupRoleWhat they receive
metallic bladesExperimentallaryngoscope blade material
Receives: Device: metal reusable blades MacIntosh
plastic laryngoscope bladesActive comparatorLaryngoscope Blade Material
Receives: Device: Single use plastic blades HEINE XP®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The frequency of patients presenting a post-operative sore throat whose intensity is above 4 on a visual analogue scale (VAS) graded from 0 (no pain) to 10 (unbearable pain) collected at the discharge of the post-anesthesia care unit (PACU).

    Measured: Two years

Secondary outcomes (12)
  1. The frequency of patients presenting a post-operative sore throat whose intensity is different from 0/10 without swallowing

    Measured: 2 years

  2. The pain intensity will be measured at the discharge of the post-anesthesia care unit (PACU) with a slide ruler displaying a visual analogue scale graded from 0 (no pain) to 10 (unbearable pain) on the blinded face

    The pain will be evaluated everyday during two days. If the pain persists, it will be evaluated everyday till the pain disappears or till the end of the patient participation (seven days).

    Measured: seven days

  3. the degree of voice modification on a VAS

    dysphonia

    Measured: Seven days

  4. the sore throat VAS during swallowing.

    dysphagia

    Measured: seven days

  5. jaw pain

    Measured: seven days

  6. lips injuries

    Measured: seven days

  7. dental injuries

    Measured: seven days

  8. blood on the blade

    Measured: seven days

  9. the intubation difficulty score (IDS)

    Measured: one day

  10. the frequency of difficult intubation

    Measured: Two years

  11. the frequency of change of blade during the tracheal intubation procedure

    Measured: two years

  12. the tracheal intubation duration.

    Measured: one day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 May 2010 (estimated)
  2. Study startSep 2010
  3. Primary completionSep 2015
  4. Study completionSep 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
712 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01118533
Sponsor's protocol ID
K080902
Acronym
MPLIT
Status last verified
May 2016
First submitted
29 Mar 2010
Last updated
10 Jun 2016
Results posted
No
Data monitoring committee
Yes

Publications

  • Amour J, Marmion F, Birenbaum A, Nicolas-Robin A, Coriat P, Riou B, Langeron O. Comparison of plastic single-use and metal reusable laryngoscope blades for orotracheal intubation during rapid sequence induction of anesthesia. Anesthesiology. 2006 Jan;104(1):60-4. doi: 10.1097/00000542-200601000-00011.

    PubMed 16394691
  • Maktabi MA, Smith RB, Todd MM. Is routine endotracheal intubation as safe as we think or wish? Anesthesiology. 2003 Aug;99(2):247-8. doi: 10.1097/00000542-200308000-00002. No abstract available.

    PubMed 12883393

Questions about this trial

What is this clinical trial studying?

A study testing metal reusable blades MacIntosh and Single use plastic blades HEINE XP® in people with Tracheal Intubation Morbidity and Sore Throat, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The frequency of patients presenting a post-operative sore throat whose intensity is above 4 on a visual analogue scale (VAS) graded from 0 (no pain) to 10 (unbearable pain) collected at the discharge of the post-anesthesia care unit (PACU). (time frame: Two years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01118533, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jun 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in